Literature DB >> 16456490

Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations.

Roy J Kim1, Clara Malattia, Michaela Allen, Thomas Moshang, Mohamad Maghnie.   

Abstract

The management of central diabetes insipidus has been greatly simplified by the introduction of desmopressin (DDAVP). Its ease of administration, safety and tolerability make DDAVP the first line agent for outpatient treatment of central diabetes insipidus. The major complication of DDAVP therapy is water intoxication and hyponatremia. The risk of hyponatremia can be reduced by careful dose titration when initiating therapy and by close monitoring of serum osmolality when DDAVP is used with other medications affecting water balance. Herein we review the adverse effects of DDAVP and its predecessor, vasopressin, as well as discuss important clinical considerations when using these agents to treat central diabetes insipidus.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 16456490

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN： 1565-4753


  12 in total

1.  Desmopressin : safety considerations in patients with chronic renal disease.

Authors:  Domenic A Sica; Todd W B Gehr
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Quality of life in the patients with central diabetes insipidus assessed by Nagasaki Diabetes Insipidus Questionnaire.

Authors:  Aya Nozaki; Takao Ando; Satoru Akazawa; Tsuyoshi Satoh; Ikuko Sagara; Ichiro Horie; Misa Imaizumi; Toshiro Usa; Robert T Yanagisawa; Atsushi Kawakami
Journal:  Endocrine       Date:  2015-05-30       Impact factor: 3.633

Review 3.  Desmopressin therapy in children and adults: pharmacological considerations and clinical implications.

Authors:  Xinyi Chin; Shao Wei Teo; Soo Ting Lim; Yong Hong Ng; How Chuan Han; Fabian Yap
Journal:  Eur J Clin Pharmacol       Date:  2022-02-23       Impact factor: 2.953

Review 4.  The Emerging Role of Copeptin.

Authors:  R Jalleh; D J Torpy
Journal:  Clin Biochem Rev       Date:  2021-02

5.  3T renal (23)Na-MRI: effects of desmopressin in patients with central diabetes insipidus.

Authors:  Stefan Haneder; Henrik J Michaely; Simon Konstandin; Lothar R Schad; John N Morelli; Bernhard K Krämer; Stefan O Schoenberg; Alexander Lammert
Journal:  MAGMA       Date:  2013-04-06       Impact factor: 2.310

Review 6.  Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin.

Authors:  D F Alonso; G V Ripoll; J Garona; N B Iannucci; D E Gomez
Journal:  Curr Pharm Biotechnol       Date:  2011-11       Impact factor: 2.837

7.  A case of central diabetes insipidus associated with cardiac dysfunction.

Authors:  Nobumasa Ohara; Masanori Kaneko; Tatsuya Suwabe; Tasuku Yoshie; Hiroyuki Kuwano; Katsuya Ebe; Toshio Fujita; Koichi Fuse; Kenzo Kaneko; Kyuzi Kamoi
Journal:  Clin Case Rep       Date:  2016-10-11

8.  Soluble (pro)renin receptor via β-catenin enhances urine concentration capability as a target of liver X receptor.

Authors:  Xiaohan Lu; Fei Wang; Chuanming Xu; Sunny Soodvilai; Kexin Peng; Jiahui Su; Long Zhao; Kevin T Yang; Yumei Feng; Shu-Feng Zhou; Jan-Åke Gustafsson; Tianxin Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-16       Impact factor: 11.205

9.  Prolonged urinary leakage in the postoperative period of renal hydatic cyst treatment with oral desmopressin: a case report.

Authors:  Cavit Ceylan; Ozkan Baytok; Serkan Doğan; Metin Yığman
Journal:  J Med Case Rep       Date:  2012-10-05

10.  A rare case of pituitrin-induced delayed encephalopathy.

Authors:  Tingting Xu; Lijun Zhu; Jiachun Feng; Shaokuan Feng
Journal:  Pak J Med Sci       Date:  2014-09       Impact factor: 1.088
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.